Metal-organic frameworks (MOFs) have shown great potential in designing theranostic probes for cancer diagnosis and therapy due to their unique properties, including versatile structures and composition, tunable particle and pore size, enormous porosity, high surface area, and intrinsic biodegradability. In this study, we demonstrate novel MOF-based theranostic Fe 3 O 4 @UiO-66 core-shell composites constructed by in situ growth of a UiO-66 MOF shell on a Fe 3 O 4 core for simultaneous drug delivery and magnetic resonance (MR) imaging. In the composites, the UiO-66 shell is devoted for encapsulating the drug, whereas the Fe 3 O 4 core serves as a MR contrast agent. The Fe 3 O 4 @UiO-66 core-shell composites show good biocompatibility, high drug loading capacity, sustained drug release, and outstanding MR imaging capability, as well as effective chemotherapeutic efficacy, demonstrating the feasibility of designing theranostic Fe 3 O 4 @UiO-66 core-shell composites for cancer diagnosis and therapy.
Introduction
Metal-organic frameworks (MOFs) are an emerging class of organic-inorganic hybrid porous materials built from metal ion or cluster nodes and organic linkers, which have already been explored for a variety of applications, including separation, catalysis, and gas storage. 1, 2 In recent years, MOFs have been scaled down to nanometer sizes to form nanoscale MOFs and focused on their preliminary biomedical applications in drug delivery and bioimaging. [3] [4] [5] [6] MOFs have been successfully employed as drug delivery vehicles owing to their unique properties suitable for drug loading and release. 7 Different from most of the existing pure organic and inorganic carrier materials, MOFs have exceptionally high surface area and enormous porosity, which are favorable for entrapment of large amounts of drugs, tunable pore size and hydrophilic-hydrophobic cavities to host a variety of drugs with different physico-chemical properties, controllable host-guest interactions and intrinsic biodegradability. Since Ferey's group 8 rst reported the ability of iron-based MOFs as drug carriers to encapsulate ibuprofen molecules at unprecedented levels and deliver the drug continuously, with no burst effect, many researchers have developed other MOFs, such as UMCM-1, ZIF-8, MIL-53, MOF-74, Gd-MOF, UiO-66, Cu-BTC, and chiral MOFs, for drug delivery.
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Paramagnetic metal ions-containing MOFs are also promising as contrast agents for magnetic resonance (MR) imaging. 19, 20 Compared with clinical small molecule contrast agents, the framework construction features ensure that MOFs not only possess large amounts of paramagnetic metal centers, but also exhibit enhanced per-metal-based relaxivity. Lin and co-workers rst demonstrated the potential of Gd-based MOFs as MR contrast agents. 21 The Gd-based MOFs show excellent longitudinal relaxivity; however, leaching of the free Gd 3+ ions causes nephrogenic systemic brosis, 22 which precludes their clinical applications. Given that Mn 2+ and Fe 3+ ions are also known as potent paramagnetic metal ions, with much lower toxicity than Gd 3+ ions, low toxic Mn-based MOFs and non-toxic iron-carboxylate MOFs, have been developed for T 1 /T 2 -weighted MR contrast enhancement. [23] [24] [25] The biocompatibility of Mn/FeMOFs-based MR contrast agents has been improved, but the moderate relaxivity of Fe/Mn-MOFs still limits the imaging sensitivity, which hinders their practical applications. To circumvent the problem and make full use of the extraordinary drug encapsulation capacity of MOFs, the incorporation of nanoparticles with unique magnetic properties into MOFs is indeed an effective strategy.
Iron oxide nanoparticles are prevalent in MR imaging due to their ability to signicantly shorten transverse relaxation time and excellent biocompatibility. 26 Moreover, various formulations of iron oxide nanoparticles, such as ferumoxsil, ferrixan and ferumoxide, have already been approved by the FDA as T 2 12, 15 The coordination of a Zr(IV)-cluster and linear ligands forms a cubic rigid 3D porous structure comprising octahedral cavities with a diameter of 1.1 nm and tetrahedral cavities with a diameter of 0.6 nm.
38
The presence of Zr-O clusters, numerous open cavities, metal sites and amphiphilic character make UiO-66 advantageous for capturing and releasing anticancer drugs such as doxorubicin (DOX) based on the strong coordination interactions between the hydroxyl groups in DOX and Zr(IV) centers in UiO-66. In addition, the toxicity of UiO-66 has been demonstrated to be relatively low. 37 39 The as-synthesized Fe 3 O 4 nanoparticles were spherical with a diameter of 150 nm (Fig. 1A ) and in the cubic phase (JCPDS: 19-0629) (Fig. 1E) . The Fe 3 -O 4 @UiO-66 composites were then synthesized by an in situ selfassembly of UiO-66 on the surface of Fe 3 O 4 to obtain the coreshell theranostic agent. In a typical process, Fe 3 O 4 nanoparticles were directly dispersed into the synthetic precursor of UiO-66 composed of ZrCl 4 , NH 2 -H 2 BDC and DMF, and the reaction was accomplished through a simple hydrothermal procedure. The developed method avoids time-consuming layer-by-layer MOF growth and further modication of core particles, which is much simpler than most of the previous methods of synthesizing MOF-based core-shell composites.
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To control the morphology of the core-shell composites, the concentrations of the precursors of UiO-66 were optimized. Aer mixing with different concentrations of UiO- (Fig. 1B) . Either the UiO-66 shell was too thick or no shell was formed if the ratio was higher or lower than the optimized ratio. Thus, the Fe 3 O 4 @UiO-66 core-shell composites synthesized under the optimized condition were used for the following experiments. Furthermore, high angle annular dark eld scanning transmission electron microscopy (HAADF-STEM) and elemental mapping analysis were used to verify the core-shell structure of the Fe 3 -O 4 @UiO-66 composite ( Fig. 1C and D) .
A clear contrast between the core and shell was obtained wherein the core appeared dark, whereas the shell appeared bright. Moreover, the EDS (energy dispersive spectrometry) line scanning data and elemental mapping analysis reveal that the Fe and Zr elements were distributed in the core and shell, respectively. All the results demonstrated the successful formation of a core-shell structure for the Fe 3 O 4 @UiO-66 composite.
The simultaneous existence of the characteristic peaks of Fe 3 O 4 and UiO-66 in the X-ray diffraction (XRD) pattern of Fe 3 O 4 @UiO-66 indicated the successful formation of a UiO-66 shell on the surface of Fe 3 O 4 nanoparticles without altering their crystallinity (Fig. 1E) 
Drug loading/release of Fe 3 O 4 @UiO-66 composites
The stability of the nanocarrier in a wide pH range from basic to acidic is essential for drug loading/release. Thus, we investigated the stability of the as-synthesized (Fig. 3A) or the morphology (Fig. S7, ESI †) (Fig. 3B) . Moreover, the presence of characteristic absorption bands (indicated by green dashed rectangle) of DOX in the spectra of Fe 3 O 4 @UiO-66-DOX also indicated the incorporation of DOX molecules into Fe 3 O 4 @UiO-66 (Fig. 3C) .
The drug loading capacity increased from 2.5 to 66.3 wt% as the amount of DOX increased from 0.15 to 15 mg (Fig. 3D) . Furthermore, the drug loading capacity increased with the thickness of the UiO-66 shell (Table S2 , ESI †). The DOX loading capacity of Fe 3 O 4 @UiO-66 could reach 66.3 wt% with an ultrahigh loading content of 2.0 mg DOX per mg composites, which is almost the highest DOX payload among the MOFs carriers. 25, [44] [45] [46] The impressive result was meaningful for clinical applications, because the administration of high dosages could be realized using a small amount of composites.
The high drug loading capacity of Fe 3 O 4 @UiO-66 composites was probably attributed to the large surface area of the UiO-66 shell and the interactions between DOX and UiO-66. A remarkable uorescence quenching of DOX along with color change from brown to wine for the Fe 3 O 4 @UiO-66-DOX dispersion conrmed the strong interaction between DOX and Fe 3 O 4 @UiO-66 ( Fig. S5 and S8 , ESI †). Potential interactions include p-p stacking between the aromatic anthracycline of DOX and the aromatic pore walls of UiO-66, hydrogen bonding between the oxygen atoms of DOX and the amino groups in UiO-66, van der Waals forces, electrostatic interactions, and coordination bonding. 47 Among the above interactions, stable coordination bonding between the deprotonated hydroxyls in DOX and the numerous Zr sites in the UiO-66 framework played the leading role in drug loading, as conrmed by ultravioletvisible (UV-Vis) spectroscopy and X-ray photoelectron spectroscopy (XPS) (Fig. 3E and S9 , ESI †). Red shi of the UV-Vis spectrum of Fe 3 O 4 @UiO-66-DOX in comparison with that of DOX aer DOX loading into Fe 3 O 4 @UiO-66 indicates the formation of a DOX-Zr complex in the Fe 3 O 4 @UiO-66 framework, which is also supported by the similar spectral modi-cation of DOX with free Zr(IV) ions (Fig. S9 †) (Fig. 3E) . The binding energy of Zr 3d shiing to lower levels aer DOX encapsulation could be attributed to electron transfer due to binding of DOX to active Zr sites. [48] [49] [50] The formation of coordination bonds between DOX and metal centres (Zr, Fe, Zn) has also been described previously.
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Owing to the strong coordination bonding of DOX-Zr, the Fe 3 -O 4 @UiO-66 showed a remarkable and efficient DOX payload.
The DOX release behavior of the Fe 3 O 4 @UiO-66-DOX composites was investigated at different pH values (4.0, 5.0, 6.0, and 7.4). The time-dependent accumulated drug release (ADR) curves showed a slow and sustained release pattern without any burst effect (Fig. 3F) . The release rate would generate a stable drug concentration and provide sufficient time for the Fe 3 -O 4 @UiO-66-DOX to accumulate at the tumor site. As shown in Fig. 3F , about 36.1% and 21.6% of the DOX were released in 41 days at pH 4.0 and 5.0, respectively, whereas 17.1% and 13.8% of DOX were released at pH 6.0 and 7.4, indicating the sensitivity of Fe 3 O 4 @UiO-66-DOX to acidic tumor microenvironments. The pH-responsive DOX release was controlled by the drug-matrix interactions under acidic conditions. At acidic pH, the amino group in DOX was easily protonated, giving DOX a positive charge. Moreover, the surface zeta potential of Fe 3 -O 4 @UiO-66 became less negative in acidic conditions (À9.8 AE 1.1 mV at pH 4.0 and À25.7 AE 5.2 mV at pH 7.4). Thus, the electrostatic interactions between Fe 3 O 4 @UiO-66 and DOX were weakened, which promoted the drug release in acidic conditions. 53 Moreover, the breakage of the coordination bonds between the protonated hydroxyls in DOX and Zr sites under acidic conditions would accelerate the DOX release. In addition to the pH dependent DOX release, the tendency of endogenous phosphate salts in the endosomes to coordinate to the Zr sites also facilitates the release of DOX from the Fe 3 O 4 @UiO-66 composites. 52, 54 These results indicate that Fe 3 O 4 @UiO-66 nanocarriers could deliver the drug to tumor tissue sustainably and effectively, which would be benecial for the diminishing of toxic side effects and decreasing of patient discomfort. (Fig. 4A) . In contrast, the Fe 3 O 4 @-UiO-66-DOX exhibited signicant increase in anticancer activity against HeLa cells with the increase of the loaded DOX concentration (Fig. 4B) (Fig. 4C) . As expected, the 3T3 cells treated with (Fig. 5A) .
In vitro cytotoxicity
The feasibility of the Fe 3 O 4 @UiO-66 composites for in vivo MR imaging was also tested. A signicant darkening effect was observed in the liver region of the Kunming mouse at 10 min post-injection of Fe 3 O 4 @UiO-66 composites (400 mL, 5 mg mL À1 , 24 mg Fe per kg), indicating the ability of Fe 3 O 4 @UiO-66 to enhance in vivo T 2 -weighted images (Fig. 5B) . The dramatic T 2 signal intensity decrease is probably due to the phagocytosis of the Fe 3 O 4 @UiO-66 composites by the liver macrophage cells in reticuloendothelial systems (RES). 55 Considering the excellent 
Biodistribution and toxicology studies
The potential toxic effects of nanomaterials are a major concern for their biomedical applications. Thus, the metabolism, biodistribution and long-term toxicity of the as-synthesized Fe 3 -O 4 @UiO-66 core-shell composites were systematically investigated. For metabolism study, the T 2 -weighted images of the Kunming mouse injected with the composites were collected aer 1, 7, 14 and 30 days of injection. Strong darkening effect aer injection and signal recovery at 30 days postinjection were observed in the liver region, but no timedependent darkening effect was observed in the urinary bladder, indicating that Fe 3 O 4 @UiO-66 was not excreted from the kidneys but from the liver (Fig. 5B) . For biodistribution study, the major organs (heart, liver, spleen, lung, kidney) of the mice treated with Fe 3 O 4 @UiO-66 for 1, 7 and 30 days were collected, weighed and solubilized by aqua regia for AAS measurement of Fe and ICP-MS determination of Zr concentrations, respectively. As expected and consistent with the T 2 -weighted MR images, high levels of Fe and Zr contents mainly accumulated in mononuclear phagocyte systems such as the spleen and liver ( Fig. 6A and S10, ESI †). The Fe levels in all measured organs constantly decreased as the post-injection time prolonged and nearly dropped back to the normal levels aer 30 days, except for the liver, in which the Fe content was slightly higher than the control. It was noteworthy that Zr was not detected in the heart, lung or kidney due to the absence of Zr in the organism and no accumulation of Fe 3 O 4 @UiO-66 in these organs. In addition, the Zr levels in the liver and spleen could be gradually metabolized over time, which was consistent with the biodistribution of Fe. For in vivo long-term toxicity, the body weight and the blood analysis were evaluated. The body weights of the control group and the experimental group treated with Fe 3 O 4 @UiO-66 maintained similar increases over 30 days, and no death or signicant body weight drop were observed in the experimental group, illustrating that the injection of the Fe 3 O 4 @UiO-66 composites did not perceivably interfere with the growth of the mice (Fig. S11 , ESI †). Blood analysis parameters, including liver function markers (total protein, TP; albumin, ALB; globulin GLB; alanine aminotransferase, ALT; aspartate aminotransferase, AST; alkaline phosphatase, ALKP; gamma glutamyl transaminase, GGT; total bilirubin, TBIL; direct bilirubin, DBIL) and kidney function markers (urea, UREA; creatinine, CREA; uric acid URIC), at different time points post-injection of Fe 3 O 4 @UiO-66 appeared to be normal compared with those in the control group, indicating that no obvious liver or kidney disorders were induced by the injection of Fe 3 O 4 @UiO-66 (Fig. 6B ). All these results demonstrated that the as-synthesized Fe 3 O 4 @UiO-66 was a relatively safe theranostic agent for biomedical applications.
In vivo antitumor efficacy
Inspired by the biocompatibility of Fe 3 O 4 @UiO-66 and in vitro anticancer effect of the DOX-loaded Fe 3 O 4 @UiO-66, the in vivo 
